DoW Peer Reviewed Cancer, Clinical Trial Award
This program funds cancer clinical trials in FY26 PRCRP topic areas for eligible applicants, including studies of drugs, biologics, devices, clinical guidance, or emerging technologies from pilot/first-in-human through phase III.
⚑ Clinical trial required · Patient advocates required · Animal studies not allowed · All preclinical work must be completed before award start date if needed for the trial input package; no preclinical work funded here likely beyond the trial itself (literal trial-focused mechanism)
Unit fits — one characterization, each unit's own rules
| Physical Sciences & Engineering (demo) | 70 strong | technical depth: substantial; funds applied research |
| IPPRA | 58 good | peripheral portfolio topic: public_health; signature methods: community engaged; social/behavioral work is minor; funds applied research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); clinical-trial/biomedical core — IPPRA angle is policy/community (capped) |
| Tom Love Innovation Hub | 45 partial | funds applied research; prototyping/demonstration stage; deep-tech content |
Description
Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations.
Distinctive Features:
• Applications to this award mechanism must include a clinical trial.
• Projects can range from phase 0 to phase III.
• If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial.
• Applications are required to include patient advocates.
• Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.
Apply
View on Grants.gov → CONTACT: Abigail Strock Contract Specialist <help@eBRAP.org>
Proposal brief SEE AN EXAMPLE →
A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.
Proposal shell · Department of Defense (BAA-style) conventions SEE A DOD EXAMPLE →
Funder-faithful document skeletons — Department of Defense (BAA-style)'s document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.